In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

Submitted by admin on January 15, 2019 - 10:08am
Source: 
Endpoints
News Tags: 
China
FDA
Btk inhibitors
BeiGene
cancer
Headline: 
In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica
snippet: 

BeiGene may have made its rep as a PD-1 pioneer in China, but it’s coming to the US with more cancer drugs in its arsenal.

Do Not Allow Advertisers to Use My Personal information